Engineering BioChoice Lignin-Based Microparticles for Applications in Veterinary Medicine

BioChoice 木质素基微粒工程在兽医学中的应用

• 批准号: 508318-2017
• 负责人: Allen, Christine
• 金额: $ 1.82万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=639969
• 关键词: Engineering; BioChoice; Lignin; Based; Microparticles

Domtar is the largest integrated producer of uncoated free sheet paper in North America. As a result they are amajor producer of lignin, a relatively low value by-product that is used as a solid fuel to generate process steamand power. Lignin, a substance in the cellular walls of plants, is the second most abundant renewable carbonsource on our planet. Domtar has recently produced high-grade USDA Certified bio-based lignin, referred to asBioChoice lignin for potential applications in the energy and chemical industries. For the first time, theproposed research intends to explore Domtar's proprietary BioChoice lignin and derivatives, to be synthesizedthrough this research, for applications in drug delivery. It is expected that this research will result in newintellectual property for Domtar and bring its proprietary material BioChoice into the pharmaceutical realm.Domtar's proprietary BioChoice Kraft lignin is produced from the black liquor of the Plymouth mill at a rate ofabout 50-100 tons per day. While the Plymouth mill was the first commercial demonstration plant, Domtar alsohas 11 other pulp mills, four of which are in Canada. It is Domtar's intention to build out their lignin capacity inmany or all of these facilities as demands and markets grow. Given lignin's low cost, sustainability, resistanceto oxidation, biocompatibility and biodegradability it is of interest for use in biomedical applications. Yet todate, very few studies have explored lignin and its derivatives for applications in drug delivery. The goal of thecurrent research is to synthesize and fully characterize BioChoice lignin-based microparticles that providesustained release of drugs for veterinary applications. The global animal healthcare market, was valued atUS$27.8 billion in 2013 and is expected to reach US$41.9 billion in 2019. New technologies that providecontrolled delivery of drugs for maintenance of good health and treatment of diseases in companion andcommercial animals will further advance this fast growing industry. Growth in this industry in Canada willresult in new opportunities for scientists trained in chemistry as well as pharmaceutical and veterinary sciences.

Domtar是北美最大的非涂布自由页纸综合生产商。因此，他们是木质素的主要生产商，木质素是一种价值相对较低的副产品，用作固体燃料来产生工艺蒸汽和电力。木质素是植物细胞壁中的一种物质，是地球上第二丰富的可再生碳源。Domtar最近生产了美国农业部认证的高等级生物木质素，称为BioChoice木质素，用于能源和化工行业的潜在应用。这项拟议的研究首次打算探索Domtar的专利BioChoice木质素及其衍生物，这些木质素和衍生物将通过本研究合成，用于药物输送。预计这项研究将为Domtar带来新的知识产权，并将其专利材料BioChoice带入制药领域。Domtar的专利BioChoice硫酸盐木质素以每天约50-100吨的速度从普利茅斯工厂的黑液中生产。虽然普利茅斯纸浆厂是第一家商业示范工厂，但Domtar还拥有其他11家纸浆厂，其中4家位于加拿大。随着需求和市场的增长，Domtar打算在许多或所有这些设施中扩大木质素能力。鉴于木质素的低成本、可持续性、抗氧化性、生物相容性和生物降解性，它在生物医学应用中具有重要的应用价值。然而，到目前为止，很少有研究探索木质素及其衍生物在药物输送中的应用。目前研究的目标是合成并充分表征基于BioChoice木质素的微粒，为兽医应用提供受抑制的药物释放。全球动物保健市场，2013年价值278亿美元，预计2019年将达到419亿美元。新技术提供了不受控制的药物输送，以维持同伴和商业动物的健康和治疗疾病，这些技术将进一步推动这一快速增长的行业。加拿大这一行业的增长将为受过化学、制药和兽医科学培训的科学家带来新的机会。